PEI authors publish correction concerning LIONEX test
An evaluation of a number of COVID-19 antigen tests was recently published by Scheiblauer Heinrich, Filomena Angela, Nitsche Andreas, Puyskens Andreas, Corman Victor M, Drosten Christian, Zwirglmaier Karin, Lange Constanze, Emmerich Petra, Müller Michael, Knauer Olivia, Nübling C Micha:
Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021. Euro Surveill. 2021;26(44):2100441. https://doi.org/10.2807/1560-7917.ES.2021.26.44.2100441
In this publication and in a separate list by the Paul-Ehrlich-Institut (PEI), it was mentioned that a number of tests including the one of LIONEX GmbH had shown 0% sensitivity.
A correction regarding this misinterpretation of the PEI evaluation has now been published. Below is the message received by LIONEX on 2022-01-20 from the Journal EUROSURVEILLANCE: „We would like to inform you that a Correction has been published today for the article in question: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.27.3.210120c „.
We welcome this step by the authors and EUROSURVEILLANCE in support of the high scientific standards to which LIONEX is committed.
An additional independent evaluation of the LIONEX COVID-19 antigen test by Labor LIMBACH, Peine confirmed adequate performance of the LIONEX test without any faint bands or background.
LIONEX is growing biotech company with exceptional commitment to the problems of tropical diseases such as TB and HIV infection. It is a partner of BioRegioN, a highly active biotech oriented region in Germany. LIONEX has excellent facilities and expertise in recombinant DNA technology, production of high quality recombinant proteins and monoclonal antibodies (mAbs) for research and diagnostics. In the last 22 years, more than 400 recombinant proteins of M. tuberculosis have already been produced by LIONEX and are available in significant quantities. Corresponding mAbs are available for a series of mycobacterial antigens. This fact shall be of considerable advantage for developing new diagnostic products (antigen and antibody detection) for TB. Prof. Singh, the CEO of LIONEX, has been engaged in research on mycobacterial antigens for the last 30 years. He has coordinated and / or supervised research projects funded by the WHO, European Commission, German Science Foundation and German Government. Prof. Singh is involved in national and international research projects on TB, HIV, Buruli ulcer, Malaria and mycobacterial genetics. He has coordinated several EU projects „NEW TB Drugs“, FASTEST-TB“, „NOPERSIST“ and is currently coordinating DEMO-NOPERSIST (FP7 project).
Company-Contact
LIONEX GmbH
Mahavir Prof. Dr. Singh
Salzdahlumer Str. 196
38126 Braunschweig
Phone: 05312601266
Fax: 05316180654
E-Mail: info@lionex.de
Url: http://www.lionex.de
Press
LIONEX GmbH
Mahavir Dr. SINGH
Salzdahlumer Str. 196
38126 Braunschweig
Phone: 05312601266
Fax: 05316180654
E-Mail: info@lionex.de
Url: http://www.lionex.de
Die Bildrechte liegen bei dem Verfasser der Mitteilung.
